ELEV · Elevation Oncology, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $6.88M | - | $9.39M | $6.55M | $6.01M | - | $7.42M | $6.03M | $7.29M | - |
| SG&A | $3.96M | - | $3.84M | $4.41M | $3.86M | - | $3.50M | $3.81M | $4.35M | - |
| Total Operating Expenses | $14.22M | - | $13.23M | $10.96M | $9.87M | - | $10.92M | $9.83M | $16.75M | - |
| D&A | $5.0K | - | - | - | $10.0K | - | - | - | $10.0K | - |
| Operating Income | ($14.22M) | - | ($13.23M) | ($10.96M) | ($9.87M) | - | ($10.92M) | ($9.83M) | ($16.75M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $6.0K | - | $12.0K | $11.0K | $11.0K | - | $11.0K | $5.0K | $5.0K | - |
| Net Income | ($14.21M) | - | ($12.88M) | ($10.46M) | ($10.71M) | - | ($10.64M) | ($10.11M) | ($17.06M) | - |
| EPS - Basic | ($0.24) | - | ($0.22) | ($0.18) | ($0.23) | - | ($0.25) | ($0.37) | ($0.72) | - |
| EPS - Diluted | ($0.24) | - | ($0.22) | ($0.19) | ($0.23) | - | ($0.25) | ($0.37) | ($0.72) | - |
Balance Sheet
| Line item | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $60.49M | $49.46M | $48.20M | $59.45M | $90.63M | $49.26M | $54.88M | $106.33M | $55.90M | $45.92M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $492.0K | $559.0K | $2.63M | $344.0K | $435.0K | $507.0K | $3.64M | $5.24M | $4.04M | $6.36M |
| Current Assets | $82.19M | $94.73M | $105.32M | $113.57M | $107.89M | $87.96M | $98.80M | $109.42M | $75.83M | $92.98M |
| Total Assets | $82.22M | $95.63M | $106.30M | $114.60M | $108.96M | $89.09M | $99.97M | $110.37M | $76.90M | $94.16M |
| Current Liabilities | $4.24M | $4.47M | $5.93M | $2.76M | $2.33M | $4.14M | $7.61M | $8.42M | $13.53M | $15.69M |
| Long-term Debt | $31.25M | $31.13M | $31.02M | $30.92M | $30.81M | $30.14M | $29.95M | $29.77M | $29.60M | $29.43M |
| Total Liabilities | $35.49M | $35.60M | $36.95M | $33.68M | $33.14M | $34.28M | $37.56M | $38.19M | $43.13M | $45.13M |
| Stockholders' Equity | $46.73M | $60.02M | $69.36M | $80.92M | $75.82M | $54.81M | $62.42M | $72.18M | $33.76M | $49.03M |
| Retained Earnings | ($254.67M) | ($240.46M) | ($230.02M) | ($217.14M) | ($206.68M) | ($195.97M) | ($188.07M) | ($177.44M) | ($167.32M) | ($150.27M) |
Cash Flow
| Line item | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($12.71M) | - | - | - | ($9.57M) | - | - | - | ($16.83M) | - |
| Investing Cash Flow | $23.76M | - | - | - | $20.70M | - | - | - | $26.60M | - |
| Financing Cash Flow | ($17.0K) | - | - | - | $30.25M | - | - | - | $216.0K | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -17.3% | - | -12.1% | -9.1% | -9.8% | - | -10.6% | -9.2% | -22.2% | - |
| Return on equity | -30.4% | - | -18.6% | -12.9% | -14.1% | - | -17.0% | -14.0% | -50.5% | - |
| Return on invested capital | -14.4% | - | -10.4% | -7.7% | -7.3% | - | -9.3% | -7.6% | -20.9% | - |
| Liquidity | ||||||||||
| Current ratio | 19.40 | 21.21 | 17.77 | 41.10 | 46.22 | 21.22 | 12.99 | 13.00 | 5.60 | 5.93 |
| Quick ratio | 19.40 | 21.21 | 17.77 | 41.10 | 46.22 | 21.22 | 12.99 | 13.00 | 5.60 | 5.93 |
| Cash ratio | 14.28 | 11.07 | 8.13 | 21.52 | 38.83 | 11.88 | 7.21 | 12.63 | 4.13 | 2.93 |
| Leverage | ||||||||||
| Debt / Equity | 0.67 | 0.52 | 0.45 | 0.38 | 0.41 | 0.55 | 0.48 | 0.41 | 0.88 | 0.60 |
| Debt / Assets | 0.38 | 0.33 | 0.29 | 0.27 | 0.28 | 0.34 | 0.30 | 0.27 | 0.38 | 0.31 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.76 | 1.59 | 1.53 | 1.42 | 1.44 | 1.63 | 1.60 | 1.53 | 2.28 | 1.92 |
| Liabilities / Assets | 0.43 | 0.37 | 0.35 | 0.29 | 0.30 | 0.38 | 0.38 | 0.35 | 0.56 | 0.48 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -44.0% | - | -21.1% | -11.5% | 41.1% | - | 71.7% | 51.1% | 3.6% | - |
| Net income growth (YoY) | -32.7% | - | -21.1% | -3.5% | 37.2% | - | 72.6% | 49.3% | -235.1% | - |
| EPS growth (YoY) | -4.3% | - | 12.0% | 48.6% | 68.1% | - | 85.0% | 57.0% | 88.7% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -38.4% | 9.5% | 11.1% | 12.1% | 124.6% | 11.8% | -7.0% | -31.0% | -72.7% | -65.2% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Elevation Oncology against the 5 most active filers in the same SIC group.